Lisa Diller

Activating mutations in ALK provide a therapeutic target in neuroblastoma

Rani E. George, Takaomi Sanda, Megan Hanna et al. · Nature · 2008 · 885 citations · Full text

Receptor Tyrosine Kinase, Tumor Suppressor, Radiation Oncology +4

p53 functions as a cell cycle control protein in osteosarcomas.

Lisa Diller, J Kassel, C. Nelson et al. · Molecular and Cellular Biology · 1990 · 766 citations

Wild-type P53, Oncogenic Agent, P53 Gene +14

High Risk of Subsequent Neoplasms Continues With Extended Follow-Up of Childhood Hodgkin’s Disease: Report From the Late Effects Study Group

Yutaka Yasui, Leslie L. Robison, Jillian M. Birch et al. · Journal of Clinical Oncology · 2003 · 617 citations

Cardiovascular Status in Long-Term Survivors of Hodgkin's Disease Treated With Chest Radiotherapy

M. Jacob Adams, Stuart R. Lipsitz, Steven D. Colan et al. · Journal of Clinical Oncology · 2004 · 494 citations · Full text

The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: A report from the childhood cancer survivor study

Daniel M. Green, Pamela J. Goodman, John Whitton et al. · Pediatric Blood & Cancer · 2013 · 446 citations · Full text